$CYCC
Cyclacel Pharmaceuticals, Inc.

2023 Q2 Form 10-Q Financial Statement

#000155837023009443 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $373.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.575M $1.645M
YoY Change -0.32% 2.49%
% of Gross Profit
Research & Development $4.727M $5.674M
YoY Change 12.41% 14.53%
% of Gross Profit
Depreciation & Amortization $8.000K $8.000K
YoY Change 0.0% -11.11%
% of Gross Profit
Operating Expenses $6.302M $7.319M
YoY Change 8.94% 11.59%
Operating Profit -$5.929M -$7.319M
YoY Change 2.49% 11.59%
Interest Expense $1.000K $29.00K
YoY Change -99.56% -12.12%
% of Operating Profit
Other Income/Expense, Net -$105.0K $195.0K
YoY Change -146.46% -85.15%
Pretax Income -$6.034M -$7.124M
YoY Change 8.54% 35.8%
Income Tax -$586.0K -$1.320M
% Of Pretax Income
Net Earnings -$5.448M -$5.804M
YoY Change 19.08% 41.29%
Net Earnings / Revenue -1460.59%
Basic Earnings Per Share -$0.44 -$0.47
Diluted Earnings Per Share -$0.44 -$0.47
COMMON SHARES
Basic Shares Outstanding 12.54M 12.54M
Diluted Shares Outstanding 12.55M 12.54M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.16M $11.44M
YoY Change -65.04% -61.42%
Cash & Equivalents $10.20M $11.40M
Short-Term Investments
Other Short-Term Assets $2.186M $595.0K
YoY Change 2667.09% -61.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.29M $18.97M
YoY Change -52.32% -48.13%
LONG-TERM ASSETS
Property, Plant & Equipment $24.00K $31.00K
YoY Change -50.0% -45.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.000M $2.916M
YoY Change -67.32% -2.15%
Total Long-Term Assets $1.148M $3.086M
YoY Change -64.88% 1.11%
TOTAL ASSETS
Total Short-Term Assets $15.29M $18.97M
Total Long-Term Assets $1.148M $3.086M
Total Assets $16.44M $22.06M
YoY Change -53.48% -44.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.169M $2.509M
YoY Change -1.63% -11.96%
Accrued Expenses $4.577M $4.829M
YoY Change 62.25% 43.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.746M $7.338M
YoY Change 34.22% 18.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $66.00K $80.00K
YoY Change -41.59% 433.33%
Total Long-Term Liabilities $66.00K $80.00K
YoY Change -41.59% 433.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.746M $7.338M
Total Long-Term Liabilities $66.00K $80.00K
Total Liabilities $6.812M $7.418M
YoY Change 32.55% 19.28%
SHAREHOLDERS EQUITY
Retained Earnings -$417.4M -$412.0M
YoY Change 6.04% 5.88%
Common Stock $9.000K $9.000K
YoY Change -18.18% -10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.136M $10.15M
YoY Change
Total Liabilities & Shareholders Equity $16.44M $22.06M
YoY Change -53.48% -44.33%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$5.448M -$5.804M
YoY Change 19.08% 41.29%
Depreciation, Depletion And Amortization $8.000K $8.000K
YoY Change 0.0% -11.11%
Cash From Operating Activities -$1.305M -$6.861M
YoY Change -31.85% 1.27%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $6.000K
YoY Change -100.0% 50.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$6.000K
YoY Change -100.0% 50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -51.00K -50.00K
YoY Change -103.46% 0.0%
NET CHANGE
Cash From Operating Activities -1.305M -6.861M
Cash From Investing Activities 0.000 -6.000K
Cash From Financing Activities -51.00K -50.00K
Net Change In Cash -1.356M -6.910M
YoY Change 205.41% -0.14%
FREE CASH FLOW
Cash From Operating Activities -$1.305M -$6.861M
Capital Expenditures $0.00 $6.000K
Free Cash Flow -$1.305M -$6.867M
YoY Change -31.75% 1.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2916000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12539189
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9993135
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Cyclacel Pharmaceuticals, Inc.
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12539189
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12539189
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001130166
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2022Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2023Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2023Q1 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3117100
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3117100
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-50626
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1707622
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Connell Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Berkeley Heights
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07922
CY2023Q1 dei City Area Code
CityAreaCode
908
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
517-7330
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12539189
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11435000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18345000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7539000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6066000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
18974000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
24411000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
139000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2916000
CY2023Q1 us-gaap Assets
Assets
22060000
CY2022Q4 us-gaap Assets
Assets
27501000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2509000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2561000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4829000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4831000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7338000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7392000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
80000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106000
CY2023Q1 us-gaap Liabilities
Liabilities
7418000
CY2022Q4 us-gaap Liabilities
Liabilities
7498000
CY2023Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3117100
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3117100
CY2023Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
4494000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
4494000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12539189
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12539189
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
423324000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
422973000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1224000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1316000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-411961000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406157000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10148000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15509000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22060000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27501000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5674000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4954000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1645000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1605000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7319000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
6559000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7319000
CY2022Q1 us-gaap Depreciation
Depreciation
9000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
401000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6559000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-87000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
116000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
166000
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1280000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
195000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1313000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7124000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5246000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1320000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1138000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5804000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4108000
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
50000
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
50000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5854000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4158000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12539189
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9993135
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5804000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4108000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5171000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5803000
CY2023Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
5263000
CY2022Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-5878000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5712000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4183000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37263000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
380000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2022Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-5878000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5803000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4108000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
33410000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15509000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
401000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2023Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
5263000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5171000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5804000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10148000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5804000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4108000
CY2023Q1 us-gaap Depreciation
Depreciation
8000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11400000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
380000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-26000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-15000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1234000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4126000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-206000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1085000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6861000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6775000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
CY2023Q1 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
50000
CY2022Q1 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
50000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-50000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-50000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-91000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6910000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6920000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18345000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36559000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11435000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29639000
CY2023Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
116000
CY2022Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
4000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
CY2023Q1 cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2022Q1 cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6428274
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5809637
CY2023Q1 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
6117000
CY2022Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
4664000
CY2023Q1 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
827000
CY2022Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
976000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
595000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
425000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7539000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6066000
CY2023Q1 cycc Deposits Held By Related Party
DepositsHeldByRelatedParty
2900000
CY2023Q1 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4392000
CY2022Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3611000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
214000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
333000
CY2023Q1 cycc Other Current Liabilities Reversal
OtherCurrentLiabilitiesReversal
-223000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
887000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4829000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4831000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
17949
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
14686
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
17634
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
15435
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
57000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
66000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
38000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
161000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
401000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
380000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
11000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
265000
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0

Files In Submission

Name View Source Status
cycc-20230331_cal.xml Edgar Link unprocessable
0001558370-23-009443-index-headers.html Edgar Link pending
0001558370-23-009443-index.html Edgar Link pending
0001558370-23-009443.txt Edgar Link pending
0001558370-23-009443-xbrl.zip Edgar Link pending
cycc-20230331.xsd Edgar Link pending
cycc-20230331x10q.htm Edgar Link pending
cycc-20230331xex31d1.htm Edgar Link pending
cycc-20230331xex31d2.htm Edgar Link pending
cycc-20230331xex32d1.htm Edgar Link pending
cycc-20230331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
cycc-20230331_def.xml Edgar Link unprocessable
cycc-20230331_lab.xml Edgar Link unprocessable
cycc-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cycc-20230331x10q_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending